Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease

Brain

Volumn 132, Issue 5, 2009, Pages 1355-1365

  Jack Jr , Clifford R ^a   Lowe, Val J ^a   Weigand, Stephen D ^a   Wiste, Heather J ^a   Senjem, Matthew L ^a   Knopman, David S ^a   Shiung, Maria M ^a   Gunter, Jeffrey L ^a   Boeve, Bradley F ^a   Kemp, Bradley J ^a   Weiner, Michael ^b   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimers disease; Amyloid imaging; Magnetic resonance imaging, longitudinal imaging; Mild cognitive impairment; Pittsburgh compound B

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BRAIN ATROPHY; BRAIN VENTRICLE DILATATION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 66549106850     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp062     Document Type: Article

References (79)

1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. Washington, DC: American Psychiatric Association; 1994.
3. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid( 1-42) in Alzheimer disease: differences between early- and late-onset alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680 (Pubitemid 29266465)
4. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60: 145-147
5. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-434 (Pubitemid 46425701)
6. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64: 834-841 (Pubitemid 40316322)
7. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000; 95: 721-725
8. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
9. Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, Quinn JF, et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 2008; 70: 828-833
10. Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 2003; 362: 1121-1122 (Pubitemid 37222338)
11. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomar-kers reject autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-1702 (Pubitemid 37521622)
12. Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, et al. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord| 2004; 18: 190-195 (Pubitemid 40076147)
13. Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27: 394-401. (Pubitemid 43185324)
14. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008; 39: 619-633 (Pubitemid 350117638)
15. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-508 (Pubitemid 46263180)
16. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, et al. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in de?nite Alzheimer's disease. Brain 2007; 130: 2320-2326 (Pubitemid 47327622)
17. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866 (Pubitemid 44684508)
18. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebro-spinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519 (Pubitemid 43358072)
19. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid( 42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349 (Pubitemid 46425688)
20. Folstein MF, Folstein SE, McHugh PR. ''Mini-mental state''. A practical method for grading the cognitive state of patients for the clinician. Psychiatr Res 1975; 12: 189-198
21. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. ET imaging of amyloid deposition in patients with mild cognitive mpairment. Neurobiol Aging 2008; 29: 1456-1465
22. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial egistered brain magnetic resonance imaging to measure disease rogression in Alzheimer disease: power calculations and estimates f sample size to detect treatment effects. Arch Neurol 2000; 57: 339-344 (Pubitemid 30140520)
23. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997; 16: 623-629 (Pubitemid 127767641)
24. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-910
25. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002; 58: 1476-1482 (Pubitemid 34552952)
26. Gunter JL, Shiung MM, Manduca A, Jack CR, Jr. Methodologica considerations for measuring rates of brain atrophy. J Magn Reson Imaging 2003; 18: 16-24. (Pubitemid 36791264)
27. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, et al. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and rejection of biological activity. J Neural Transm 2004; 111: 247-272 (Pubitemid 38316604)
28. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234 (Pubitemid 43238346)
29. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645
30. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004; 62: 925-931 (Pubitemid 38435780)
31. Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008a; 27: 685-691
32. Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58: 750-757 (Pubitemid 34211554)
33. Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008b; 131: 665-680
34. Jack CR, Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992; 42: 183-188
35. Jack CR, Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-489 (Pubitemid 30647242)
36. Jack CR, Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591-600. (Pubitemid 38252801)
37. Jack CR, Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65: 1227-1231 (Pubitemid 41508215)
38. Jack CR, Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology 1989; 172: 549-554 (Pubitemid 19184904)
39. Jack CR, Jr, Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, Gunter JL, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008c; 70: 1740-1752
40. Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008; 63: 72-80.
41. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006; 63: 674-681
42. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-234 (Pubitemid 47525398)
43. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006; 30: 436-443
44. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-1606 (Pubitemid 46717985)
45. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319 (Pubitemid 38269583)
46. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991; 48: 725-728
47. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-1309
48. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008; 35: 2169-2181
49. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007; 130: 2607-2615 (Pubitemid 47511709)
50. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-1972 (Pubitemid 46657441)
51. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-2754 (Pubitemid 36702542)
52. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944 (Pubitemid 14076461)
53. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [ 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452 (Pubitemid 44214969)
54. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects. Brain 2008; Ahead of print. ISSN 1460-2156; doi:10.1093/brain/awn320 (published online 28 November 2008).
55. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414 (Pubitemid 23346995)
56. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004; 3: 519-527 (Pubitemid 39485859)
57. O'Brien PC. The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics 1983; 39: 787-794
58. Perneger TV. What's wrong with Bonferroni adjustments. Bmj 1998; 316: 1236-1238 (Pubitemid 28171344)
59. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992 (Pubitemid 33143977)
60. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844 (Pubitemid 350033975)
61. Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-1212 (Pubitemid 46608468)
62. Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods 2008; 172: 277-282
63. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006; 5: 828-834 (Pubitemid 44715810)
64. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725 (Pubitemid 46763260)
65. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204 (Pubitemid 350294674)
66. Senjem ML, Lowe V, Kemp B, Weigand S, Knopman D, Boeve B, et al. Automated ROI analysis of 11C Pittsburgh compound B images using structural magnetic resonance imaging atlases. Alzheimer's Dementia 2008; 4 (Suppl 1).
67. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003; 61: 487-492 (Pubitemid 37025365)
68. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998; 17: 87-97. (Pubitemid 128742012)
69. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiol Aging 2008; Ahead of print. ISSN 1558-11497
70. Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, et al. Longitudinal cerebral blood ?ow and amyloid deposition: an emerging pattern? J Nucl Med 2008; 49: 1465-1471
71. Tang-Wai DF, Knopman DS, Geda YE, Edland SD, Smith GE, Ivnik RJ, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol 2003; 60: 1777-1781 (Pubitemid 37521636)
72. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580
73. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single- subject brain. Neuroimage 2002; 15: 273-289
74. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neuro?brillary tangle stage. Neuroimage 2008; 42: 559-567
75. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688-1697
76. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003; 339: 99-102. (Pubitemid 36254786)
77. Whitwell JL, Jack CR, Jr, Parisi JE, Knopman DS, Boeve BF, Petersen RC, et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 2007; 130: 1148-1158 (Pubitemid 47355599)
78. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurobrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008; 71: 743-749
79. Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol 2005; 57: 896-903. (Pubitemid 40798628)